RecruitingPhase 3NCT05722938

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Studying Syringocystadenoma papilliferum

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Biotest
Principal Investigator: Ricard Ferrer Roca, Dr.
Hospital Vall d'Hebron
Intervention: Trimodulin(drug)
Enrollment: 590 target
Eligibility: 18 years · All sexes
Timeline: 2023 – 2028

Study locations (30)

Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States
University of California San Francisco-Fresno, Fresno, California, United States
UC Davis Health, Sacramento, California, United States
Augusta University, Augusta, Georgia, United States
Sparrow Clinical Research Institute, Lansing, Michigan, United States
William Beaumont Hospital, Royal Oak, Michigan, United States
University of Missouri Clinical Research Center, Columbia, Missouri, United States
Hannibal Clinic, Hannibal, Missouri, United States
Mercury Street Medical Group, Butte, Montana, United States
St. Michael's Medical Center, Newark, New Jersey, United States
Buffalo VA Medical Center, Buffalo, New York, United States
Lenox Hill Hospital, New York, New York, United States
Wake Forest Baptist, Winston-Salem, North Carolina, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05722938 on ClinicalTrials.gov

Other trials for Syringocystadenoma papilliferum

Additional recruiting or active studies for the same condition.

See all trials for Syringocystadenoma papilliferum →

← Back to all trials